Skip to main content
Presentation
Long-term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials. Italian Society of Rheumatology (SIR) 2017 Congress, Rimini, Italy, Nov. 2017.
Italian Society of Rheumatology (SIR) 2017 Congress (2017)
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
November, 2017
Citation Information
Philip Mease and et.al.. "Long-term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials. Italian Society of Rheumatology (SIR) 2017 Congress, Rimini, Italy, Nov. 2017." Italian Society of Rheumatology (SIR) 2017 Congress (2017)
Available at: http://works.bepress.com/philip-mease/209/